Pharmaceutical Business review

Mylan Q2 revenues surge

Mylan‘s net earnings were $146.99m, compared to $86.93m for the same period in the prior year.

The company has posted earnings from operations as $280.47m for the second quarter ended 30 June 2011, as compared to $194.59m for the same period in 2010.

For the six months ended 30 June 2011 total revenues were $3.02bn, compared to $2.66bn for the same period in 2010.

Net earnings were $251.53m for the six months ended 30 June 2011, as compared to $181.2m for the same period prior year.

The company’s earnings from operations for the six months ended 30 June 2011 were $492.15m, as compared to $393.09m for the same period in 2010.

Mylan chief financial officer John Sheehan said during the second quarter they have completed their share repurchase program by purchasing approximately 14.8million shares for a total of $350m, thereby maintaining discipline with respect to the number of outstanding shares.